Eupraxia Pharmaceuticals
11:00 AM - 11:15 AM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Eupraxia's lead product candidate, EP-104, is currently in Phase 2 development for the treatment of pain
Ticker:
EPRX
Exchange:
TSX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
2012
Main Therapeutic Focus:
Inflammation
Lead Product in Development:
EP104
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
